August 8, 2024 Usually associated with warmer areas, the legendary sport fish is a rare sight in the state Blurry shapes just below the surface of the Chesapeake Bay, multiple tarpon school together in waters near Hoopers Island Lighthouse on Aug. 1. …
Tess Mann Atelier announces a strategic shift to prioritize evening, cocktail, resort, and bespoke designs, while maintaining select bridal offerings. SILVER POINT, TENNESSEE, UNITED STATES, August 8, 2024 /EINPresswire.com/ -- Tess Mann Atelier, a US- …
Second Quarter 2024 Highlights Revenue of $255.8 million Gross Margin of 33.6% Adjusted gross margin of 35.0%(1) Net income to common shareholders of $12.0 million Adjusted EBITDA(1) of $55.4 million Basic and diluted net income per share of $0.08 Adjusted …
On track to submit ReNu BLA by the end of 2025 Enrollment in second Phase 3 complete; significantly ahead of expectations Subgroup analysis demonstrated most severe (KL4) subjects responded comparably to moderate (KL3) CANTON, Mass., Aug. 08, 2024 (GLOBE …
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial …
SANTA CLARA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystems, today announced it will host an Executive Conference on the …
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, …
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 …
– Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2’24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2’24 Adjusted EBITDA …
Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be reported 2H 2024 Enrollment continues in Phase 2 PN and …
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart’s oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute …
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H’26 Phase 2 trial in …
No dose-limiting toxicities or concerning side effects in our Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors …
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 — MDD program on track with Phase 3 study expected to initiate in H2 2024 — Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in …
Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to …
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growth New drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and …
ENGLEWOOD, Colo., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the second quarter 2024 and recent corporate highlights. Recent Corporate Highlights Net-Zero 1 …
Q2'24 Marketplace revenue accelerated to 14% YoY, marking the third consecutive quarter of double-digit growth Consolidated GAAP Net Loss of $68.7 million1; Non-GAAP Adjusted EBITDA of $55.6 million, up 23% YoY Repurchased $61 million worth of shares …
GRAND CAYMAN, Cayman Islands, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), together with its subsidiaries which is engaged in the business of tokenized Real-World Assets (“RWAs”) initially in the form of …
CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the commencement of a proposed underwritten public offering of its common stock. All shares of …
05 days 19:48:33
